Potential Acquisition of FUSE-AI GmbH by Pineapple Power Corporation

Xlife Sciences AG announced ongoing discussions for the acquisition of its portfolio company, FUSE-AI GmbH, by Pineapple Power Corporation PLC. This potential deal is valued at EUR 80-90 million. If completed, it would involve a full acquisition of all FUSE-AI shares through shares issued by Pineapple Power. This mechanism would constitute a reverse takeover under UK listing rules.

This acquisition could enable FUSE-AI to access global capital markets, enhancing its AI-powered solutions for clinical diagnostics. Xlife Sciences AG, owning 42.25% of FUSE-AI, stands to gain significantly from this transaction, marking a pivotal step for FUSE-AI's growth.

FUSE-AI is recognized for its innovation in medical AI, particularly with "Prostate.Carcinoma.ai". Operating in over 42 countries, the company is well-positioned for increased market presence and technological advancement.